Skip to main content
DeprescribingStatins· 6 min read· in Health

Stopping Statins Safe for Older Adults Without Heart Disease, Trial Finds

A major clinical trial shows that older adults taking statins for primary prevention can safely stop their medication without increasing their risk of cardiovascular events. The findings offer a reassuring path to reduce daily pill burdens for seniors who have never had a heart attack or stroke.

By Pedro Almeida

Share this story

Listen

Older adults who take a daily statin to prevent a first heart attack can safely stop the medication without triggering a spike in cardiovascular emergencies. New research presented at the American Heart Association Scientific Sessions 2026 demonstrates that discontinuing the cholesterol drugs is noninferior to staying on them for primary prevention.[1][5]

The STREAM trial, published November 7 in the New England Journal of Medicine, evaluated the safety of halting statin therapy in elderly patients. The study focused exclusively on primary prevention, meaning the participants had no prior history of cardiovascular disease.[3][4]

Researchers found that withdrawing the cholesterol-lowering medication did not compromise patient safety. Older adults who stopped taking their statins did not experience a statistically significant increase in heart attacks, strokes, or cardiovascular mortality compared to those who maintained their daily dose.[3][5]

"It is generally safe for older adults without a history of cardiovascular disease to discontinue statins for primary prevention," the study authors concluded in their November 7 publication. The findings offer a reassuring, evidence-based path forward for patients looking to reduce their daily medication burden.[4][5]

The Polypharmacy Problem

The medical community has increasingly recognized the risks associated with polypharmacy, typically defined as taking five or more prescription medications daily. For adults over the age of 75, managing multiple prescriptions is a common and sometimes overwhelming logistical challenge.

Each additional medication increases the risk of adverse drug interactions, cognitive side effects, and accidental dosing errors. Statins, while highly effective at lowering cholesterol, are not immune to these complications, particularly as patients age and their metabolic clearance naturally slows down.

Muscle aches and joint pain are among the most frequently reported side effects of statin therapy in older populations. These symptoms can discourage physical activity, which is itself a critical component of maintaining cardiovascular health and overall mobility in later life.

Polypharmacy remains a significant burden for older adults, increasing the risk of drug interactions and side effects.

By demonstrating that statins can be safely withdrawn in specific cases, the STREAM trial provides clinicians with rigorous backing to deprescribe. This represents a significant shift from the traditional medical approach, which often prioritized adding protective medications rather than removing them.[2][3]

Inside the STREAM Trial

The trial's design specifically targeted a demographic that is often underrepresented in cardiovascular research: the elderly. Historically, clinical guidelines for statin use have been extrapolated from studies conducted on middle-aged adults, leaving a gap in evidence for patients in their late seventies and eighties.[4]

Participants in the STREAM trial were randomized into two groups: one that continued their established statin regimen and another that safely discontinued the medication. Researchers then tracked their cardiovascular health outcomes over a multi-year follow-up period to monitor for adverse events.[3][4]

The primary endpoint of the study was a composite of major adverse cardiovascular events. The data revealed that the discontinuation group did not cross the pre-specified noninferiority margin, meaning their risk remained statistically comparable to the continuation group.[3][5]

However, as noted by cardiovascular news outlet TCTMD, the decision to stop is "not risk free." Patients who discontinued their statins did see a predictable, albeit modest, increase in their low-density lipoprotein (LDL) cholesterol levels during the follow-up period.[2]

Despite this rise in circulating cholesterol, the crucial takeaway was that the elevated LDL did not translate into a surge of clinical emergencies. The absolute risk of experiencing a first-time heart attack or stroke remained reassuringly low for these older adults.[2][4]

Primary Versus Secondary Prevention

A critical distinction in the STREAM trial is its exclusive focus on primary prevention. This refers to treating patients who have risk factors for heart disease, such as elevated cholesterol, but have never actually suffered a cardiovascular event.[1][3]

The safety of stopping statins applies strictly to primary prevention—patients who have never had a cardiovascular event.

Secondary prevention, by contrast, involves patients who have already survived a heart attack, stroke, or undergone stent placement. For this secondary group, the medical consensus remains absolute: statins are life-saving, stabilize arterial plaque, and should rarely be discontinued.[1]

The calculus changes significantly for primary prevention in advanced age. The time required to accrue the preventive benefits of a statin often exceeds the patient's life expectancy, making the immediate side effects a more pressing concern than long-term cholesterol management.

Geriatricians have long argued that preventive guidelines must account for the diminishing returns of certain medications late in life. The NEJM data provides the rigorous clinical validation needed to support these individualized, patient-centered prescribing decisions.[4]

Weighing Risks and Benefits

The findings from the American Heart Association meetings in Chicago underscore the importance of shared decision-making. Doctors are now better equipped to discuss the nuanced trade-offs of statin therapy with their older patients, rather than relying on blanket age-based recommendations.[1][5]

For a 78-year-old patient experiencing unexplained muscle fatigue, the STREAM data suggests that a trial off the statin is a reasonable and safe clinical option. If the muscle pain resolves, the medication can be permanently retired with minimal anxiety about impending heart disease.[3]

Conversely, older adults who tolerate their statins perfectly well may choose to continue their regimen. The trial does not mandate discontinuation; rather, it removes the clinical dogma that stopping the medication is inherently dangerous for this specific population.[2][4]

Healthcare providers must also consider the psychological impact of deprescribing. Many patients have been told for decades that their statin is a vital shield against heart disease, and withdrawing it requires careful communication and reassurance from their care team.

Illustration: Deprescribing unnecessary medications can simplify daily routines and reduce the risk of adverse side effects.

Changing Clinical Practice

The publication of the STREAM trial is expected to influence future iterations of cardiovascular care guidelines. Major medical societies regularly update their recommendations based on landmark NEJM publications, and deprescribing protocols are gaining traction globally.[4]

This shift aligns with broader public health initiatives aimed at reducing unnecessary medical interventions. By safely eliminating a daily pill, healthcare systems can reduce the risk of adverse events while lowering prescription costs for patients on fixed incomes.

The November 7 release of the data marks a milestone in geriatric cardiology. It proves that rigorous, large-scale trials can successfully challenge entrenched prescribing habits and deliver highly practical benefits for aging populations.[3][5]

Moving forward, researchers hope to identify specific biomarkers that might predict which older adults are the best candidates for statin withdrawal. Until then, the STREAM trial serves as the definitive baseline for primary prevention deprescribing.[2]

The central goal of geriatric medicine is to maximize quality of life rather than simply extending it through pharmaceutical means. Safely removing a medication that no longer serves a clear purpose is a profound step toward that objective.

Patients currently taking statins should never stop their medication abruptly without consulting their physician. The distinction between primary and secondary prevention is a clinical judgment that requires a comprehensive review of a patient's complete medical history.[1]

Patients currently taking statins should never stop their medication abruptly without consulting their physician.

As the medical community digests the findings from Chicago, the immediate takeaway is one of empowerment. Older adults and their doctors now have the evidence they need to simplify medication routines, prioritizing daily comfort without compromising cardiovascular safety.[5]

Key points

  1. Older adults taking statins for primary prevention can safely stop the medication without a significant increase in cardiovascular events.
  2. The STREAM trial focused exclusively on patients who have never suffered a heart attack or stroke.
  3. Discontinuing statins can help reduce polypharmacy and alleviate side effects like muscle pain in elderly populations.
  4. Patients with a history of cardiovascular disease (secondary prevention) should continue their statin therapy as prescribed.

What we don’t know

  • Whether specific genetic biomarkers could identify a small subset of primary prevention patients who might still benefit from continuing statins.
  • How the discontinuation of statins affects long-term cognitive health, an area of ongoing debate in geriatric neurology.
  • Current coverage is largely limited to medical trade publications; broader mainstream media interpretation of the trial remains to be seen.
Geriatricians 40%Preventive Cardiologists 40%Patient Advocates 20%
Geriatricians
Advocate for deprescribing to reduce polypharmacy, prioritizing quality of life and minimizing side effects in older age.
Preventive Cardiologists
Emphasize that while stopping is safe for primary prevention, patients with prior heart events must remain on their statins.
Patient Advocates
Value shared decision-making, allowing seniors to weigh the burden of daily pills against marginal preventive benefits.

Perspectives this story doesn't cover

  • Pharmaceutical manufacturers of generic statins
  • Primary care physicians managing routine geriatric care

Sources

Source coverage

5 outlets

3 viewpoints surfaced

Geriatricians 40%Preventive Cardiologists 40%Patient Advocates 20%
  1. [1]American Heart AssociationPreventive Cardiologists

    Discontinuing statins generally safe for older adults without heart disease

    Read on American Heart Association →
  2. [2]TCTMDPreventive Cardiologists

    Elderly Patients on Statins for Primary Prevention Can Stop, but It's Not Risk Free: STREAM

    Read on TCTMD →
  3. [3]HCPLivePatient Advocates

    STREAM: Statin Discontinuation Noninferior in Older Adults Without CVD

    Read on HCPLive →
  4. [4]The New England Journal of MedicineGeriatricians

    Discontinuing Statins in Older Adults without Cardiovascular Disease

    Read on The New England Journal of Medicine →
  5. [5]Medical XpressPatient Advocates

    AHA: Discontinuing statins noninferior to continuation in older adults without known cardiovascular disease

    Read on Medical Xpress →
Listen

Comments

Stay informed

Every angle. Every day.

Get Health stories with full source coverage and perspective breakdowns, free every day.